David E. Lazar - 13 Feb 2026 Form 4 Insider Report for MAINZ BIOMED N.V. (MYNZ)

Role
Director
Signature
/s/ David E. Lazar
Issuer symbol
MYNZ
Transactions as of
13 Feb 2026
Net transactions value
$0
Form type
4
Filing time
03 Mar 2026, 10:13:06 UTC
Previous filing
05 Jan 2026
Next filing
24 Mar 2026
SEC
View on sec.gov

Sponsored

Quoteable Key Fact

"David E. Lazar filed Form 4 for MAINZ BIOMED N.V. (MYNZ) on 03 Mar 2026."

Quick Takeaways

  • This page summarizes David E. Lazar's Form 4 filing for MAINZ BIOMED N.V. (MYNZ).
  • 3 reported transactions and 3 derivative rows are listed below.
  • Filing timestamp: 03 Mar 2026, 10:13.

What Changed

  • Previous filing in this sequence was filed on 05 Jan 2026.
  • Current net transaction value: $0.

Why This Matters

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Official SEC Source

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

See Original Filing

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Lazar David E. Director 44, TOWER 100, THE TOWERS, WINSTON CHURCHILL, PAITILLA, PANAMA CITY, PANAMA /s/ David E. Lazar 03 Mar 2026 0001932843

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding MYNZ Ordinary Shares 0 13 Feb 2026 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MYNZ Series A Preferred Shares Award +1,000,000 1,000,000 13 Feb 2026 Ordinary Shares 0 Direct F2, F3, F4, F5
transaction MYNZ Series B Preferred Shares Award +1,000,000 1,000,000 13 Feb 2026 Ordinary Shares 0 Direct F2, F3, F4, F5
transaction MYNZ Series C Preferred Shares Award +1,000,000 1,000,000 13 Feb 2026 Ordinary Shares 0 Direct F2, F3, F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 No ordinary shares are beneficially owned.
F2 On February 13, 2026 David E. Lazar (the "Reporting Person") and Mainz Biomed N.V. (the "Company") entered into a securies purchase agreement (the "Purchase Agreement") pursuant to which the Reporting Person acquired 1,000,000 Series A Preferred Shares, 1,000,000 Series B Preferred Shares, and 1,000,000 Series C Preferred Shares (collectively, the "First Closing Shares"), at a price of $1.00 per share, for a total purchase price of $3,000,000. Pursuant to the Purchase Agreement, the Reporting Person will also acquire, at a subsequent closing promptly following effectiveness of the Stockholder Approval (as defined below), 1,000,000 Series D Preferred Shares and 1,000,000 Series E Preferred Shares (collectively, the "Second Closing Shares" and, together with the First Closing Shares, the "Preferred Shares"), at a price of $1.50 per share, for an additional purchase price of $3,000,000.
F3 The First Closing Shares are not convertible into ordinary shares until Stockholder Approval is obtained. Following Stockholder Approval, each of the First Closing Shares will be convertible into 9 ordinary shares and each of the Second Closing Shares will be convertible into 225 ordinary shares, subject to certain ownership limitations. No Preferred Shares will be convertible until the Company's stockholders approve (a) an increase in the Company's authorized ordinary shares to at least 900,000,000, (b) the conversion of all Preferred Shares into ordinary shares in compliance with the rules and regulations of the Nasdaq Capital Market, (c) a reverse stock split, and (d) the election of the Reporting Person and his designees to the Company's Board of Directors (collectively, the "Stockholder Approval").
F4 Following receipt by the Company of the Stockholder Approval, the Preferred Stock will be convertible into ordinary shares at the option of the Reporting Person for no additional consideration.
F5 Each class of Preferred Stock is perpetual and therefore has no expiration date.

Sponsored